| Question 1: Dose painting or dose escalation (V150) to dominant lesion (DL or GTV) of prostate cancer is clinically attractive technique. What is the reasonable coverage that can be achieved when evaluated in post-operative PSI plans? |
| Reference: | R. J. Ellis, H. Zhou, E. Kim E, et al. Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biological target volumes identified with SPECT/CT capromab pendetide. Brachytherapy, 6(1): 16-25, 2007.
J. Muenkel, B. J. Traughber, Z. Xu Z, et al. Comparison of 125I and 103Pd Isotopes in Escalating Dose to Intraprostatic Lesions for Low Dose Rate Prostate Brachytherapy: Dosimetry and Acute Toxicity. Journal of the Oncology Research, 3(1): 01-14, 2019. |
| Choice A: | <50% |
| Choice B: | 50-60% |
| Choice C: | 60-70% |
| Choice D: | 70-80% |
| Choice E: | >80% |
| Question 2: Regardless of the radionuclide used for prostate seed implantation, the transrectal ultrasound (TRUS)-guided permanent prostate brachytherapy planning approach recommended by the American Brachytherapy Society is (are): |
| Reference: | B.J. Davis, et al. American Brachytherapy Society Consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 11 (2012) 6-19.
https://www.americanbrachytherapy.org/consensus-statements/prostate |
| Choice A: | Preplanning |
| Choice B: | Intraoperative |
| Choice C: | Preplanning or Intraoperative |
| Choice D: | None of the above |
| Question 3: AAPM TG-128 Quality assurance tests for prostate brachytherapy ultrasound systems list several tests and action levels to be done on US units used for LDR prostate implants at which frequency: |
| Reference: | D. Pfeiffer et al. AAPM TG 128. Med Phys. 35(12), 2008. |
| Choice A: | Annual |
| Choice B: | Monthly |
| Choice C: | Weekly |
| Choice D: | Daily |
| Question 4: The 2016 American Brachytherapy Society Guidelines for using permanent implantation of LDR brachytherapy sources (Pd-103, I-125, Cs-131) for boost or re-irradiation of lung cancers covers what dose range? |
| Reference: | A. Stewart, B. Parashar, M. Patel, et al. American Brachytherapy Society consensus guidelines for thoracic brachytherapy of lung cancer. Brachytherapy 15, 1-11 (2016). |
| Choice A: | 45 to 60 Gy |
| Choice B: | 50 to 80 Gy |
| Choice C: | 80 to 100 Gy |
| Choice D: | 100 to 145 Gy |
| Question 5: Permanent breast seed implantation is most frequently performed using which radionuclide? |
| Reference: | J-P. Pignol, J-M. Caudrelier, J. Crook, et al. Report on the clinical outcomes of permanent breast seed implant for early-stage breast cancers. Int J Radiat Oncol Biol Phys 93, 614-621 (2015). |
| Choice A: | Pd-103 |
| Choice B: | I-125 |
| Choice C: | Cs-131 |
| Choice D: | Ir-192 |
| Question 6: "In prostate seed implantation, depositing seeds is more challenging as compared to placing a needle in the prostate while both tasks are performed by a robotic system.” |
| Reference: | D. Stoianovici et al., “MRI Stealth robot for prostate interventions,” Minim. Invasiv. Ther. Allied. Technol. 16, 241–248 (2007).
T. K. Podder, I. Buzurovic, K. Huang, T. Showalter, A. P. Dicker, and Y. Yu, “Reliability of EUCLIDIAN: An autonomous robotic system for image-guided prostate brachytherapy,” Medical Physics, 38, 96–106 (2010). |
| Choice A: | True |
| Choice B: | False |
